CCP
PBYI icon

Clough Capital Partners’s Puma Biotechnology PBYI Stock Holding History

Clough Capital Partners’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-233,100
Closed -$15.6M – 193
2016
Q3 		$15.6M Sell
233,100
-13,500
-5% -$683K 0.81% 43
2016
Q2 		$7.35M Buy
+246,600
New +$7.71M 0.39% 84
2015
Q2 		– Sell
-75,286
Closed -$17.8M – 231
2015
Q1 		$17.8M Buy
75,286
+38,886
+107% +$8.31M 0.59% 74
2014
Q4 		$6.89M Buy
+36,400
New +$8.08M 0.25% 112

Other funds holding PBYI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Clough Capital Partners's PBYI Position: Q4 2016 in Review

Clough Capital Partners sold out of Puma Biotechnology (PBYI) in Q4 2016, closing a stake of 233,100 shares — an estimated $15.6M sold.

Clough Capital Partners first reported a position in PBYI in Q4 2014 and held it in 4 quarters. The position peaked at $17.8M in Q1 2015. 128 funds tracked by Wall St. Rank hold PBYI as of Q4 2016.

  • Clough Capital Partners reported no remaining Puma Biotechnology position as of Q4 2016 after selling out during the quarter.
  • Clough Capital Partners sold 233,100 Puma Biotechnology shares in Q4 2016, an estimated $15.6M.
  • Clough Capital Partners first reported a position in Puma Biotechnology in Q4 2014 and held it in 4 quarters.
  • Clough Capital Partners's Puma Biotechnology position peaked at $17.8M in Q1 2015.
  • 128 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2016.

Based on Clough Capital Partners's 13F filing for Q4 2016, filed 14 Feb 2017.